Management of patients with painful diabetic neuropathy: clinical case report

Diabetic polyneuropathy is the most common neurological complication of diabetes mellitus (DM) and may affect about half of all patients with diabetes. Timely diagnosis and treatment of DPN can prevent such serious complications as limb numbness, severe pain during the day and night, foot ulceration and suppuration, amputation of the foot or toes, disability and even death. The combined approach to the treatment of DPN is the most effective and includes glycemic control, diet, optimal hypoglycemic therapy, management of cardiovascular diseases, educational conversations with patients, psychological support in the form of consultations with a psychologist or psychotherapy, and sufficient pathogenetic and symptomatic drug therapy of DPN. A clinical case of managing a patient with T2DM, DPN and cardiovascular diseases is described in detail. The interdisciplinary approach was used to treat the patient, which included the use of drug and non-drug therapies. The drug therapy of diabetes was adjusted, and medications to treat cardiovascular diseases were prescribed. Pathogenetic therapy of DPN remains a highly controversial issue. Among the drugs that affect the pathogenetic mechanisms of DPN, careful consideration was given to B vitamins and alpha lipoic acid. In the presented clinical case report, the patient was prescribed a combination drug containing vitamins B1, B6 and B12 as a pathogenetic therapy of DPN. A high priority in the treatment of DM and DPN is placed on raising awareness among patients about the causes and prognosis of the disease. Most patients with diabetes and DPN have psychological problems, symptoms of anxiety and depression about the disease, catastrophization of existing symptoms, poor adherence to medication due to feelings of despair and thoughts of the disease as incurable. In view of above factors, psychological methods appear as effective in the treatment of patients with diabetes and DPN. The cognitive behavioural therapy was used in the described clinical case as a psychological method. The use of CBT improved the patient’s emotional state, increased his adherence to medications and lifestyle recommendations. A positive effect in the form of decreased severity of neuropathic and autonomic symptoms of DPN was observed in as little as 10 days after treatment. At follow-up Week 12, the patient’s condition continued to improve and his work capacity increased.

diabetes mellitus, diabetic polyneuropathy, polyneuropathy, treatment, drug therapy, interdisciplinary approach

1. Dyck P.J., Kratz K.M., Karnes J.L., Litchy W.J., Klein R., Pach J.M. et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817–824. doi: 10.1212/WNL.43.4.817.

2. Albers J.W., Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014;14(8):473. doi: 10.1007/s11910-014-0473-5.

3. Armstrong D.G., Boulton A.J.M., Bus S.A. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376(24):2367–2375. doi: 10.1056/ NEJMra1615439.

4. Sadosky A., Mardekian J., Parsons B., Hopps M., Bienen E.J., Markman J. Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy. J Diabetes Complications. 2015;29(2):212–217. doi: 10.1016/j.jdiacomp.2014.10.013.

5. Ziegler D. Current Concepts in the Management of Diabetic Polyneuropathy. Current Diabetes Reviews. 2011;7:208–220. doi: 10.2174/157339911795843113.

6. Pop-Busui R., Boulton A.J., Feldman E.L., Bril V., Freeman R., Malik R.A. et al. Diabetic neuropathy: a position statement by the american diabetes association. Diabetes Care. 2017;40(1):136–154. doi: 10.2337/dc16-2042.

7. Tesfaye S., Boulton A.J., Dyck P.J., Freeman R., Horowitz M., Kempler P. et al. Diabetic Neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments on behalf of the Toronto Diabetic Neuropathy Expert Group. Diabetes Care. 2010;33(10):2285–2293. doi: 10.2337/dc10-1303.

8. Yang H., Sloan G., Ye Y., Wang S., Duan B., Tesfaye S., Gao L. New Perspective in Diabetic Neuropathy: From the Periphery to the Brain, a Call for Early Detection, and Precision Medicine. Front Endocrinol (Lausanne). 2020;10:929. doi: 10.3389/fendo.2019.00929.

9. Lauria G., Hsieh S.T., Johansson O., Kennedy W.R., Leger J.M., Mellgren S.I. et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2010;17(7):903–912. doi: 10.1111/j.1468-1331.2010.03023.x.

10. Ahmed A., Bril V., Orszag A., Paulson J., Yeung E., Ngo M. et al. Detection of diabetic sensorimotor polyneuropathy by corneal confocal microscopy in type 1 diabetes: a concurrent validity study. Diabetes Care. 2012;35(4):821–828. doi: 10.2337/dc11-1396.

11. Tesfaye S., Vileikyte L., Rayman G., Sindrup S.H., Perkins B.A., Baconja M. et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629–638. doi: 10.1002/dmrr.1225.

12. Keith M.W., Masear V., Chung K.C., Amadio P.C., Andary M., Barth R.W. et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: The treatment of carpal tunnel syndrome. J Bone Joint Surg Am. 2010;92(1):218–219. doi: 10.2106/JBJS.I.00642.

13. Strokov I.A., Fokina A.S., Strokov K.I., Drokonova О.О. Modern principles of diagnosis and treatment of diabetic polyneuropathy. Meditsinskiy sovet = Medical Council. 2014;(5):38–43. (In Russ.) doi: 10.21518/2079-701X-2014- 5-38-43.

14. Strokov I.A., Golovachyova I.A., Brand P.Y. Pregabalin in treatment of pain syndromes. Meditsinskiy sovet = Medical Council. 2013;(4):69–73. (In Russ.) doi: 10.21518/2079-701X-2013-4-69-73.

15. Agathos E., Tentolouris A., Eleftheriadou I., Katsaouni P., Nemtzas I., Petrou A. et al. Effect of alpha-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy. J Int Med Res. 2018;46(5):1779–1790. doi: 10.1177/0300060518756540.

16. Calabek B., Callaghan B., Feldman E.L. Therapy for diabetic neuropathy: an overview. Handb Clin Neurol. 2014;126:317–333. doi: 10.1016/B978-0-444-53480-4.00022-9.

17. Boulton A.J., Kempler P., Ametov A., Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev. 2013;29(5):327–333. doi: 10.1002/dmrr.2397.

18. Golovacheva V.A. Early diagnosis and treatment of diabetic and alcoholic polyneuropathy in outpatient practice. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(6):96–103. (In Russ.) doi: 10.14412/2074-2711-2020-6-96-103.

19. Golovacheva V.A., Strokov I.A. Diabetic polyneuropathy: diagnosis, prevention, and treatment. Nevrologiya, Neiropsikhiatriya, Psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):113–118. (In Russ.) doi: 10.14412/2074-2711-2020-4-113-118.

20. Parfenov V.A., Golovacheva V.A., Fadeev V.V., Volovik A.Y., Golovacheva A.A. Optimization diabetic polyneuropathy patients management using a multidisciplinary approach. Meditsinskiy sovet = Medical Council. 2017;(1S):71–79. (In Russ.) doi: 10.21518/2079-701X-2017-0-71-79.